Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 242 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: oral intake Clear all

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions: Ibrutinib, Pembrolizumab; Drug
Lead sponsor: Joshua Brody; Other
Eligibility: 18 Years to 99 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Oropharyngeal Dysphagia
Interventions: Free Water Protocol, Control / Standard Care; Other
Lead sponsor: Poudre Valley Health System; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Loveland, Colorado

Conditions: Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma
Interventions: TMZ, E7016; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glucose Transporter Type 1 Deficiency Syndrome
Interventions: UX007; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 1 Year and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • New York, New York + 2 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: ALS Nutrition App (MyDataHelps platform); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: Sucralose, Aspartame, Acesulfame-Potassium, Control; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Rhinitis, Rhinitis, Allergic, Respiratory Sounds, Dyspnea, Headache, Migraine Disorders, Arthritis, Arthralgia, Anxiety, Sleep Initiation and Maintenance Disorders, Sleep Deprivation
Interventions: Vitamin A, Vitamin B6, Vitamin C, Nicotinamide, Vitamin D3, Vitamin E, Broccoli, Spinach, Caffeine, Coffee, Axon Eyewear, Chocolate; Dietary Supplement · Other · Device
Lead sponsor: Verifomics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injuries, Spasticity, Spasm, Muscle Spasticity, Muscle Hypertonia, Muscle Spasm
Interventions: Transcutaneous spinal stimulation at 30 Hz, Transcutaneous spinal stimulation at 75 Hz, Tizanidine, Baclofen, Placebo; Other · Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Jackson, Mississippi

Conditions: Pregnancy
Interventions: Folic acid, 400 mcg/day, Folic acid 800 mcg/day; Dietary Supplement
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Meniere Disease
Interventions: Venlafaxine, Placebo oral tablet; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Healthy
Interventions: Clopidogrel, Placebo, Pantoprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions: Loncastuximab tesirine, Venetoclax; Drug
Lead sponsor: Paolo Caimi, MD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Kidney Failure, Chronic
Interventions: Tacrolimus (Arm B), Clotrimazole Troche, Tacrolimus (Arm A), Nystatin Suspension; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome
Interventions: tolvaptan, Fluid Restriction; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 56
States / cities: Birmingham, Alabama • Mobile, Alabama • Azusa, California + 46 more

Conditions: Long COVID, Long Covid19, Long Covid-19
Interventions: IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care; Drug
Lead sponsor: Kanecia Obie Zimmerman; Other
Eligibility: 18 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 50
States / cities: Opelika, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more

Conditions: Obesity, Overweight
Interventions: NNC0487-0111 (formulation D), NNC0487-0111 (formulation C); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Posterior Spine Surgery
Interventions: Spine surgery analgesic pathway, Usual Care; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity (BMI>30), Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions: Endoscopic sleeve gastroplasty (ESG); Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 22 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension
Interventions: fenofibrate, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Long COVID, Long Covid19, Long Covid-19
Interventions: Ivabradine, Ivabradine Placebo, Coordinated Care, Usual Care; Drug · Behavioral
Lead sponsor: Kanecia Obie Zimmerman; Other
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Vitamin D Deficiency
Interventions: Redoxon VI, placebo; Dietary Supplement
Lead sponsor: Oregon State University; Other
Eligibility: 55 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Corvallis, Oregon

Conditions: Diabetes, PreDiabetes
Interventions: Oral application of miracle fruit pill, Oral application of sugar candy; Other
Lead sponsor: Queens College, The City University of New York; Other
Eligibility: 45 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bayside, New York

Conditions: Retinitis Pigmentosa, X-linked Genetic Diseases
Interventions: docosahexaenoic acid OR corn/soy oil placebo; Drug
Lead sponsor: Retina Foundation of the Southwest; Other
Eligibility: 7 Years to 32 Years · Male only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Oculopharyngeal Muscular Dystrophy
Interventions: Videofluoroscopic swallowing study, Functional Oral Intake Scale, Eating Assessment Tool-10; Procedure · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Investigation of a Free Water Protocol

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)

The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2)

Metabolic Effects of Non-Nutritive Sweeteners

Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application

Electrical Neuromodulation for Modifying Spinal Network Involved in Spasticity

Folic Acid Supplementation in Pregnant Women: Dose Response

Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia

RECOVER-AUTONOMIC Platform Protocol

A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity

Evaluation of Spine Surgery Analgesic Pathway

Pilot Study of Endoscopic Sleeve Gastroplasty for Obese Patients With Heart Failure and Preserved Ejection Fraction

The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans

RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)

The Effect of Combinatorial Nutritional Supplementation on Immune Function in Healthy Older Adults

Effects of Miracle Fruit Pill Application on Food Likings and Energy Intake in Diabetic or Prediabetic Patients

DHA and X-Linked Retinitis Pigmentosa

Screening in Oculopharyngeal Muscular Dystrophy